NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
Updated: Feb 10
PERK Inhibitor
NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma
Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
Sponsor
ClinicalTrials.gov Identifier: NCT05027594
Official Title: A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma
First Posted : August 30, 2021
Click here to see details on ClinicalTrials.gov
Drug: NMS-03597812
Drug: NMS-03597812 + dexamethasone
PERK Inhibitor NMS-03597812 (Code C184373)
NMS 03597812
NMS-03597812
NMS03597812
PERK Inhibitor NMS-03597812
Location
United States, Massachusetts
United States, New York
United States, North Carolina